Elicio Therapeutics, Inc. Amortization of Debt Issuance Costs
Elicio Therapeutics, Inc. (ELTX) reported Amortization of Debt Issuance Costs of $300.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-13
- Elicio Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2025-03-31 was $300.00K.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2022-12-31 was $0.00.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2022-09-30 was $0.00.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for the quarter ending 2022-06-30 was $0.00.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for fiscal 2025 was $300.00K.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for fiscal 2021 was $1.88M, a 75.41% decline from fiscal 2020.
- Elicio Therapeutics, Inc. amortization of debt issuance costs for fiscal 2020 was $7.66M.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $300.00K 10-K · filed 2026-03-12 | |||
| 2025-03-31 | $300.00K 10-Q · filed 2026-08-13 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $0.00 derived: sum of 3 quarters · filed 2023-03-17 | $0.00 10-K · filed 2023-03-17 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-17 | $0.00 derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $0.00 derived: sum of 3 quarters · filed 2023-03-17 | $0.00 derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 derived: sum of 2 quarters · filed 2023-03-17 | $0.00 derived: sum of 3 quarters · filed 2023-03-17 | $1.88M 10-K · filed 2023-03-17 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $1.88M 10-Q · filed 2022-11-14 | $6.80M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $1.88M 10-Q · filed 2022-08-15 | $6.80M derived: sum of 3 quarters · filed 2022-08-15 | $8.99M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $1.88M 10-Q · filed 2022-05-16 | $6.80M derived: sum of 2 quarters · filed 2022-05-16 | $8.99M derived: sum of 3 quarters · filed 2022-05-16 | $9.39M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $7.11M derived: sum of 2 quarters · filed 2022-03-30 | $7.50M derived: sum of 3 quarters · filed 2022-03-30 | $7.66M 10-K · filed 2022-03-30 |
| 2020-09-30 | $2.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.58M derived: sum of 2 quarters · filed 2021-11-12 | $2.74M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $396.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $553.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $157.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |